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Technological advances are revolutionizing the way 
in which we can diagnose and screen populations for 
inborn errors of metabolism (IEM). The current state 
of knowledge allows the diagnosis of many IEM by 
detection of the aberrant gene. However, as multiple 
genetic defects may result in the same biochemical 
phenotype, most diagnosis of genetic defects in a 
clinical setting are still accompanied by an abnormal 
accumulation of the metabolites of the affected 
pathways, or unusual metabolites from alternate 
pathways. 
The advances made in the diagnosis of IEM in recent 
years have not only been in the field of discovering 
new genes, but in technical ability to detect 
intermediates of metabolism in smaller samples, with 
greater efficiency and with fewer tests. 
 
Chromatographic techniques are ideal for separation 
of compounds out of a complex mixture in a 
biological matrix based on identification of compound 
on retention time. Plasma amino acids analysis 
by cation exchange chromatography and organic 
acids determination by gas chromatography mass 
spectrometry have been widely used for diagnosis of 
aminoacidopathies and organic acidemias. 
In Pakistan, evidence on the underlying incidence 
on the genetic disorder is lacking mainly because 
of lack of diagnostic facilities. The population 
of Pakistan consists of a fine amalgamation of 
people from diverse tribal, cultural, religious and 
social backgrounds. Mortality and morbidity from 
a vast number of medical and surgical conditions 
is significant and well above compared to the 
developed countries. Although a large component of 
the human health problem in Pakistan is related to 
infection, malnutrition and other preventable causes, 
a significant proportion is linked to hereditary factors 
reflecting in the form of chromosomal, single gene 
and complex medical diseases.
This issue is focused on the newly introduced 
metabolic genetic testing services offered at 
AKUH clinical laboratory in the Section of 
Chemical Pathology for diagnosis of IEM. We 
share relevant information about the service 
offered and address the issues and challenges 
for pathologist and physicians in Pakistan. In 
addition the issue also includes tests that are being 
offered in other sections. It is hoped that with 
the introduction of these services, our efforts for 
awareness and education of our physicians will 
lead to substantial improvement in the diagnosis of 
IEM in Pakistan.
Dr Aysha Habib Khan
Chemical Pathologist
From the Editor’s Desk
Approach to a Sick Neonate with Hyperammonemia
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Diagnosis of Inborn Errors of Metabolism in 
Pakistan: Issues and Challenges
The scientific concept of inborn errors of 
metabolism (IEM) was brought forward by Sir 
Archibald Edward Garrod in early 1900s. The term 
‘inborn errors of metabolism’’ was used to describe 
the hereditary deficiency or alteration in enzyme 
reactions. Although individual IEM are relatively 
rare conditions; as a group they represent a vast and 
diverse collection of diseases that are a significant 
cause of morbidity and mortality worldwide. 
The reports in literature often quote a cumulative 
incidence varying between 1 in 1500 and 1 in 5000 
live births. 
In early 1960s, the concept of newborn screening 
(NBS) was evolved. NBS allows screening of 
newborns for disorders just after birth that can 
cause severe illness or death unless detected 
and treated early. For example phenylketonuria, 
congenital hypothyroidism, congenital adrenal 
hyperplasia (CAH), maple syrup urine disease 
(MSUD) etc. Programs are designed to provide 
early diagnosis and treatment before significant and 
irreversible damage occurs. A comprehensive NBS 
system/program consists of education, screening 
(specimen collection, transportation, and testing), 
follow-up of abnormal and unsatisfactory results, 
confirmatory testing and diagnosis, treatment and 
periodic outcome evaluation, quality assurance and 
program evaluation, validity of testing systems, 
efficiency of follow-up and intervention, and 
assessments of long-term benefits to individuals, 
families, and society. Public awareness coupled 
with professional training and family education is 
also a part of the complete NBS system. NBS has 
been demonstrated to save lives and prevent serious 
disability. Reports have shown its cost effectiveness 
and it represents a public health success. 
The criteria for inclusion of a test/disorder into a 
newborn screening program continue to evolve 
and are given in Table 1 and the disorders included 
in NBS are given in Table 2. Pakistan has as yet 
no newborn screening programme at the national 
level. The health care system is mainly hospital-
based and primary health care facilities are 
practically non-existent. A large proportion of 
Dr Aysha Habib Khan
Chemical Pathology
1 The condition sought should be an important health problem
2 There should be an accepted treatment for patient with recognized disease
3 Facilities for diagnosis and treatment should be available
4 There should be a recognizable latent or early symptomatic stage
5 There should be a suitable test or examination
6 The test should be acceptable to the population
7 The natural history of the condition, including development from latent to declared disease should  
 be adequately understood
8 There should be an agreed policy on whom to treat as patients
9 The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
 economically balanced in relation to possible expenditure on medical care as a whole
10 Case-finding should be a continuing process and not a ‘once and for all’ project
Table 1.   Wilson and Jungner Criteria used to Justify Screening for a Specific Disorder*
*Reproduced from Bulletin of the World Health Organization. Revisiting Wilson and Jugner in the genomic age: a review of screening 
criteria over the past years.
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deliveries occur at home and majority of these 
home deliveries are usually attended by unskilled 
birth attendants. Pakistan also has a very high 
consanguinity rate of 46-61 per cent due to strong 
cultural preferences. The burden of inherited disease 
is expected to be very high, and is considered to 
be a major contributor to the high infant mortality 
rate in Pakistan. Infants are not diagnosed early 
and die without the benefit of available treatment. 
In addition to this genetic counseling services are 
not available and appropriate genetic advice is not 
given to parents of these children so they often have 
the additional problems of further affected infants 
before the underlying disorder is detected. 
There is a need to consider IEM as a potential 
cause of any severe illness and to have a systemic 
approach to diagnosis and management. However,  
this was not possible as the diagnostic facilities 
were non-existent. Due to the lack of diagnostic 
facilities and absence of national registries for 
disease prevalence of various inherited diseases are 
not known. Some of the IEM like beta thalassemia, 
G6PD, congenital hypothyroidism and CAH are 
widely prevalent in our society. 
Despite undergoing major revolutions in the 
past years in the world, the field of inborn errors 
of metabolism has so far been neglected in 
Pakistan. The primary reason is non-availability 
of the diagnostic facility, lack of expertise both 
in terms of human resource as well as equipment 
needed to perform the analysis. The equipment’s 
are not only technically demanding but are very 
expensive. In addition, there is no data to reflect 
the prevalence of the defects from Pakistan. 
However, the incidence appears to be high due to 
high degree of consanguineous marriages. Aga 
Khan University Hospital Clinical Laboratory has 
now successfully acquired this technique and has 
initiated the specialized testing for diagnosis of 
IEM. The tests will be performed on state of art 
equipment for diagnosis of amino acid disorders 
and organic academia. The two techniques together 
Table 2. Recommended uniform newborn screening panel; Good Laboratory Practices for Biochemical Genetic Testing and Newborn 
Screening for Inherited Metabolic Disorders
Inborn errors of amino acid metabolism
Argininosuccinic aciduria 
Citrullinemia, type I 
Maple syrup urine disease 
Homocystinuria 
Classic phenylketonuria 
Tyrosinemia, type I 
Disorders of fatty acid oxidation 
Carnitine uptake defect (carnitine transport defect) 
Medium-chain acyl-CoA dehydrogenase deficiency 
Very long-chain acyl-CoA dehydrogenase deficiency 
Long-chain-L-3-hydroxyacyl-CoA  dehydrogenase 
deficiency 
Trifunctional protein deficiency 
Disorders of organic acid metabolism 
Propionic acidemia 
Methylmalonic acidemia (methylmalonyl-CoA 
mutase deficiency) 
Methylmalonic acidemia (cobalamin disorders) 
Isovaleric acidemia 
3-Methylcrotonyl-CoA carboxylase deficiency 
3-Hydroxy-3-methylglutaric aciduria 
Holocarboxylase synthase deficiency 
ß-Ketothiolase deficiency 
Glutaric acidemia type I 
Endocrine disorders 
Primary congenital hypothyroidism 
Congenital adrenal hyperplasia 
Hemoglobin disorders 
SS disease (sickle cell anemia) 
S, beta-thalassemia 
Other conditions 
Biotinidase deficiency 
Cystic fibrosis 
Classic galactosemia 
Hearing loss 
Severe combined immunodeficiencies 
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can diagnose a number of disorders in a suspected 
patient. Table 3 shows the IEM that has been 
diagnosed from January to July 2013 in our lab. 
Aminoacidopathies/
Organic AcidemiaN= 306, 
“When you hear hoofs, think of horses”…but do 
not forget Zebras!
Inborn errors of metabolism (IEM) comprise a large 
group of inherited disorders resulting from either an 
enzyme or a co-factor defect. Individual disorders in 
the large group of IEM are rare; however collective 
incidence of IEM is 1 in 5000 live birth, which is 
same as the incidence of congenital hypothyroidism.   
A significant proportion of IEM present during 
the neonatal or early childhood period with severe 
acute clinical manifestation. Unfortunately, for most 
Inherited Metabolic Disorders - Presenting as 
Metabolic Emergencies
Dr Bushra Afroze
Department of Paediatrics and Child Health
Physicians play an important role in the 
recognition of infants who may have an IEM and 
in the initial evaluation and stabilization of these 
patients and specific treatment. At the same time 
Chemical Pathologist has a great responsibility 
of appropriately diagnosing these conditions. A 
very close liaison is required between chemical 
pathologist and treating physician. Clinicians 
should provide related history of the patient to 
the Clinical Laboratory that helps in appropriate 
processing of the specimen and analysis; hence 
report interpretation and correct diagnosis by 
Chemical Pathologist.
It is important to progressively bring the inborn 
errors of metabolism to a higher level among 
health priorities. Challenges to the progress of the 
IEM field include huge disparities in our ethnic 
populations, high prevalence of malnutrition 
and infections, co-existence of very different 
models of public health services, unstable socio-
economic and political conditions, and difficulties 
in integrating the various stakeholders. There is a 
need to develop activities for provision of health 
services, education and research as an integrated 
package, increase training of human resources,  
expansion of access to diagnostic tests, and use 
of the neonatal screening framework to expand 
the provision of services. In a country with no 
IEM centers, there is a major need for such 
groups to work in collaboration, complementing 
each other’s capabilities, providing training, 
and developing joint projects. The integration of 
these groups into a large transnational network of 
reference centers would be our major aim for the 
coming years. 
Table 3. Aminoacidopathies and Organic acidemias Diagnosed 
at AKUH Clinical Laboratory (20th January 2013-3rd July 2013)
Total No. of Positive cases 25
Methylcobalmin defect or  7
deficiency
2-methyl,-3-OH butryl Co A 2 
dehydrogenase deficiency  
Hyperphenylealalinemia 1
Cystathionine beta synthetase  3
deficiency 
Propionic acidemia 2
Ethylmalonic aciduria 1
Urea cycle disorder 2
MSUD 1
Biotinidase or holocarboxylase 1 
deficiency  
Isovaleric acidemia 2
Glutaric aciduria 1
2-methyl butyryl glycine  1
aciduria  
Lysinuric protein intolerence 1
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disorders the early symptoms are non-specific like 
lethargy, refusal to feed, vomiting and tacypnea or 
apnea (Table 1). This often leads to consideration 
of more common causes like birth asphyxia, sepsis 
and pneumonia at the initial assessment of such 
patients. IEM are often either completely not 
considered or considered very late. This leads to 
delay in diagnosis and appropriate management and 
eventually result in devastating outcomes.
Inherited metabolic diseases with acute 
severe manifestations can be divided into five 
categories:
(1)  Disorders of the intoxication type
(2)  Disorder with reduced fasting tolerance
(3)  Disorders with disturbed energy metabolism
(4)  Disorders of neurotransmission 
(5)  Disorders in which no specific emergency   
 treatment is available.
Diagnostic emergency laboratory evaluation 
should cover all differential diagnoses that 
are therapeutically relevant and should always 
include blood glucose, serum ammonia, serum 
lactate and acid base status, serum electrolytes for 
anion gap and urine for ketones. Results of these 
should be available to treating physician within 
30 minutes. According to the clinical situation 
and biochemical derangement, special metabolic 
investigations must be initiated in parallel, which 
include acylcarnitine profiling with tandem 
mass spectrometry (in plasma or dried blood 
spots) and analysis of amino acids in plasma 
and of organic acids in urine. The results of all 
laboratory investigations relevant to the diagnosis 
of metabolic disorders for which specific 
emergency therapy exists should be available 
within 24 hour. Emergency treatment of metabolic 
disorders consists of symptomatic treatment, 
which is applied regardless of the underlying 
disorder, which does not require knowledge 
of the nature of the underlying disorder in the 
critical phase of stabilization. However, details 
of the diagnosis and in-depth knowledge of the 
disease in a particular patient is needed for the 
disease specific long-term treatment and better 
outcome. The long-term outcome is inversely 
related to the time between the onset of symptoms 
and the start of specific emergency treatment 
in the critical phase of stabilization. This often 
requires the initiation of therapy before the exact 
diagnosis is known and rapid initiation of specific 
investigations. Thus physicians having first 
encounter with such patients have an important 
role in recognizing the below-mentioned groups 
of IEM, (Table 2) getting appropriate labs and 
initiating right emergency treatment.
Table 1. Clinical Presentation of IEM
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Table 2. Categories of IEM with few examples
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1. Disorders of the Intoxication Type
This group comprises urea cycle disorders, organic 
acidopathies, amino acidopathies, fatty acid 
oxidation defects, galactosaemia and hereditary 
fructose intolerance.
Clinical presentation: Children with disorders 
of the intoxication type are typically born after 
an uneventful pregnancy and show a symptom-
free period after birth. The patient with a disorder 
of protein or fat catabolism typically develops 
symptoms in the first few days of life during the 
naturally occurring catabolic period. Symptoms 
include poor sucking, vomiting, and lethargy 
progressing to coma. Sepsis is a common diagnosis 
considered in this situation. After the neonatal 
period, catabolism is rare in the first months of life. 
Towards the end of the first year of life, however 
the risk of metabolic decompensation increases as a 
consequence of episodes of infection and protein-rich 
meals.
Principles of therapy: The oral intake of toxic 
precursors (protein in cases of disorders involving 
protein metabolism and fat in disorders involving 
fat metabolism) must be stopped. The endogenous 
catabolism of protein or fat must be reversed in 
disorders of protein or fat degradation. Specific 
detoxification measures should be instituted if 
available. However, neither protein nor fat can be 
stopped from diet for more than 48 hours. After 
initial 48 hours, only the involved amino acid in 
protein metabolic disorders and long chain length 
fatty acids in fatty acid oxidation defects are 
restricted based on the diagnosis established based 
on acylcarniitne, plasma amino acid and urine 
organic acids results.
2. Disorders with Reduced Fasting Tolerance
This group includes disorders of glucose 
homeostasis (glycogen storage diseases, disorders 
of gluconeogenesis, congenital hyperinsulinism) 
and disorders in which ketone bodies cannot be 
synthesized for use as alternative substrates once 
glycogen stores are exhausted (fatty acid oxidation 
defects, disorders of ketogenesis and ketolysis).
Clinical presentation: These disorders become 
symptomatic when the intervals between meals 
become longer or in the case of limited glucose 
supply, for example when vomiting or anorexia result 
from inter-current infection. A few patients may 
present in the neonatal period, however most present 
after infancy when nocturnal feeding is usually not 
as frequently given as in early infancy.
Principles of therapy: Glucose administration at 
the rate of the hepatic glucose production is basically 
sufficient to meet caloric demands in these disorders. 
Patients with congenital hyperinsulinism may 
need glucose much higher than the hepatic glucose 
production, which needs to be adjusted based on 
individual patient’s requirement. Forced anabolism 
is not needed in these disorders, as there is no 
intoxication due to catabolism.
3. Disorders with Disturbed Mitochondrial   
 Energy Metabolism
This group comprises defects of the pyruvate 
dehydrogenase complex and the respiratory chain.
Clinical presentation: Generalized lack of energy 
often impairs intrauterine growth and development.  
Due to presence of prominent lactic acidosis, 
perinatal asphyxia is often considered as the initial 
diagnosis in affected neonates. 
Principles of therapy: Correction of acidosis is 
a major goal. Glucose supply has to be limited, 
especially in defects of the pyruvate dehydrogenase 
complex, because a high glucose supply may 
exacerbate lactic acidosis.
4. Disorders of Neurotransmission
Acute emergency treatment is available in two 
disorders of neurotransmission: vitamin B6- and 
folinic acid-responsive seizures.
Clinical presentation: present immediately after birth 
with an epileptic encephalopathy, which is unresponsive 
to conventional anti-convulstants therapy.
Principles of therapy: In every newborn with 
epileptic encephalopathy a trial with intravenous 
pyridoxine and folinic acid should be performed.
5. Disorders with No Specific Emergency   
 Treatment available
There are many other metabolic disorders that 
may present with acute, often encephalopathic, 
manifestations (nonketotic hyperglycinaemia, 
sulphite oxidase deficiency) or that usually follow a 
chronic progressive course but may worsen during 
episodes of acute illness (congenital disorders of 
glycosylation, peroxisomal disorders).
10
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Role of Biochemical Genetics Laboratory in 
Evaluation of IEM
Laboratory evaluation for inborn errors of 
metabolism (IEM) should be undertaken in all 
patients with suggestive history examination, 
and/or abnormalities of routine laboratory tests. 
Patients with life-threatening illness should undergo 
concurrent evaluation for other conditions in 
the differential diagnosis such as sepsis, cardiac 
disease, etc. An optimal outcome of a child with 
IEM depends upon early recognition of the signs 
and symptoms of metabolic disease followed by 
prompt laboratory evaluation and 
referral to a center familiar with 
the management of these disorders. 
Delay in diagnosis may result in 
acute metabolic decompensation, 
progressive neurologic injury, or 
death.
Laboratory investigations can be 
tiered up to three levels which help 
in making diagnosis of IEM in a 
patient. 
 1. Metabolic screening panel 
  consisting of initial 
  laboratory tests
 2. Specialized testing consisting  
  of qualitative detection of 
  urine organic acids and   
  quantification of amino acids 
  in plasma, urine, CSF, etc
 3. Enzyme assay
1. Metabolic Screening Panel: 
 First Line Investigations for 
 Diagnosis of IEM
An abnormal laboratory value may be the first 
finding noted that suggests an IEM. The first line 
investigations are very important diagnostic clue 
for further confirmatory laboratory investigations 
in suspected patient of IEM. However, in some 
disorders, these laboratory abnormalities are 
only present during the episode of metabolic 
decompensation. If possible, blood and urine 
samples should be obtained for both the initial 
Dr Farhan Javed Dar
Chemical Pathology 
and specialized tests at the time of presentation. 
Samples for specialized tests should be processed 
and stored appropriately for further testing if 
indicated.
In suspected patient of IEM, following are the first 
line investigations offered at Clinical Laboratory of 
Aga Khan University Hospital. These tests provide a 
valuable clue of establishing a differential diagnosis 
as shown in Table 1.
Complete Blood Count: provides a clue to sepsis, 
which may be the trigger for a metabolic crisis. IEM 
patient may have anemia, thrombocytopenia, or 
pancytopenia. 
Arterial blood: is used to detect acid-base 
disturbances. Metabolic acidosis with an increased 
anion gap is commonly associated with organic 
acidemias. It may also may be present in amino 
Table 1. Distinguishing Biochemical Findings of IEM
MSUD: Maple syrup urine disease,
OA: Organic acidemia, 
UCD: Urea cycle disorders,
DCM: Disorders of carbohydrate 
  metabolism,
FAO: Fatty acid oxidation 
- usually absent 
± sometimes present
+ usually present
++ always present
A appropriate
H inappropriately high
L inappropriately low
11
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acid disorders, disorders of pyruvate metabolism, 
mitochondrial disorders, and disorders of 
carbohydrate metabolism. Respiratory alkalosis is 
commonly seen in urea cycle disorders as a result of 
hyperammonemia. 
Serum Electrolytes: Measurement of serum 
electrolytes is necessary to calculate the anion gap. 
A metabolic acidosis with an increased anion gap is 
commonly seen in organic acidemias.
Plasma lactate: Lactic acidosis caused by abnormal 
oxidative metabolism is a frequent finding 
in mitochondrial disorders, glycogen storage 
disorders, and disorders of gluconeogenesis.
Plasma ammonia: Significant elevations in 
ammonia are most commonly associated with 
urea cycle disorders and certain organic acidemias 
(particularly propionic and methylmalonic 
acidemias). High blood levels of ammonia may also 
be found in other amino acid disorder and other 
fatty acid oxidation defects.
Plasma Glucose: Hypoglycemia is typical of 
disorders of ketogenesis e.g. fatty acid oxidation 
disorders, glycogen storage disorders, and disorders 
of fructose metabolism. It also may occur in amino 
acid disorders, organic acidemias, and mitochondrial 
disorders.
Urine detail report: Urine detail report gives 
clue to certain IEM disorders e.g. urine specific 
gravity lowers down in number of IEM disorders 
having renal tubular dysfunction. The urine pH is 
also helpful in determining the cause of metabolic 
acidosis. Presence of ketones may also suggest 
IEM. Ketones are usually presents in patients with 
hypoglycemia and glycogen storage disease, organic 
academia. 
Urine reducing substances: Reducing substances 
in the urine is a clue to certain IEM if the urine 
dipstick is negative for glucose. Positive result may 
indicate carbohydrate intolerance disorder (e.g. 
galactosemia, hereditary fructose intolerance) or 
an amino acid disorder. However, the absence of 
reducing substances in the urine does not exclude 
these disorders.
2. Second Line Tests:
Specialized tests are performed on the basis of 
clinical context and first line of investigations. 
These tests include quantitation of amino acids, 
organic acids, carbohydrate and other metabolites, 
mucopolysaccharide separation and speciation, etc. 
Few frontline laboratory tests in this tier are:
Gas chromatography mass spectrometry 
(GCMS): of urine for diagnosis of organic 
acidemias Plasma amino acids and acyl-carnitine 
profile: by tandem mass spectrometry (TMS) 
for diagnosis of organic acidemias, urea cycle 
defects, aminoacidopathies and fatty acid 
oxidation defects.
High performance liquid chromatography 
(HPLC): for quantitative analysis of amino acids in 
blood and urine; required for diagnosis of organic 
acidemias and aminoacidopathies
CSF aminoacid analysis: CSF Glycine levels 
elevated in non-ketotic hyperglycinemia
Urinary orotic acid- in cases with hyperammonemia 
for classification of urea cycle defect
Urinary Succinylacetone in cases of tyrosinemia.
Plasma very long chain fatty acid (VLCFA) levels: 
elevated in peroxisomal disorders
Urine chromatography by thin layer chromatography 
and liquid chromatography mass spectrometry 
(LCMS); for qualitative and quantitative detection of 
sugars.
Urine purines and pyrimidines analysis by Gas 
chromatography mass spectrometry.
3. Definitive Diagnostic Tests; Enzyme Assay:
To confirm the disorder detected on specialized tests, 
a specific enzyme assays in leucocytes, plasma/serum 
or red cells, immunoassays and DNA/ Mutation 
based analysis is required. Utility of enzyme assay in 
establishing diagnosis of IEM is confirmative. These 
tests are available at highly specialized centers for 
IEM.
Biochemical Metabolic Testing At Clinical 
Laboratory AKUH:
Other than first line investigations (metabolic 
screening panel) specialized tests have been 
introduced at Clinical Laboratory AKUH. These 
tests are useful in diagnosis of disorders of amino 
acids, urine organic acids and some fatty acid 
oxidation defects. The specialized tests for IEM 
available are:
Plasma, Urine and CSF Amino Acids (Quantitative, 
Method: cation-exchange HPLC)
Urine Organic Acid (Qualitative, Method: GCMS)
Urine Succinylacetone (Quantitative, Method: GCMS)
12
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Amino acids are the building blocks of proteins 
and have many functions in the body. Amino 
acid disorders are a group of inherited metabolic 
conditions, each associated with a specific enzyme 
deficiency involved with protein metabolism 
that causes the accumulation of amino acids or 
metabolites in blood and urine. The accumulated 
compounds and metabolites are toxic, resulting in the 
clinical features of these disorders.
 
Using amino acid chromatography 22 amino 
acids can be quantified. Of these nine are 
essential amino acids. Amino acids eluted on 
chromatogram after analysis of standard prepared 
are listed in Table 1.
Principle of Amino Acid Quantification:
The amino acid analyzer (Shown in Fig. 1) 
is designed to provide accurate quantitative 
Azeema Jamil
Chemical Pathology 
Amino Acid Chromatography for the 
Diagnosis of Inborn Errors of Metabolism
analysis of amino acid mixture. It gives fully 
automatic and high speed analysis which is 
very sensitive. Basic principle of instrument is 
cation-ion exchange high performance liquid 
chromatography (HPLC). 
The sample containing a mixture of amino acids 
is loaded into a column of cation-exchange resin. 
The sample is moved down in the controlled 
column temperature along with buffer of 
required pH which is programmed to produce 
the required separation. At high temperature of 
reaction coil, ninhydrin reacts with amino acids 
present in the eluent to form colored compound. 
In elute, the amount of colored compound 
produced is directly proportional to the quantity 
of amino acids present. The amount of each 
colored compound is determined at two different 
wavelengths, 440nm and 570nm. At 440 nm 
hydroxproline and proline is measured, the rest 
are estimated at 570 nm. 
Estimation of one sample takes almost 3 hours to 
complete. The unit of reporting is µmol/l (Table 2) and 
age specific reference ranges are in used. The standard 
chromatogram of plasma amino acid is shown. 
Table 1. List of amino acids quantified in Clinical Laboratory 
of AKUH
Fig. 1. Analysis of Amino Acids is in progress
Courtesy of Section of Biochemical Genetics Laboratory,
Aga Khan University
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Organic acids are compounds with acidic 
properties and are intermediary or end product 
of metabolism Fig. 1. An enzyme defect in a 
metabolic pathway can lead to accumulation 
and increased excretion of one or more of 
organic acids in urine resulting in Organic 
Acidurias, that may lead to acute life-threatening 
illness, developmental delays, and metabolic 
decompensation. Urine organic acid analysis 
is an essential component of the workup of the 
patient suspected to have an inborn error of 
metabolism. 
Organic Acid Chromatography for the 
Diagnosis of Inborn Errors of Metabolism
Farhat Jahan
Chemical Pathology
Fig. 1. Wide range of Compounds produce Organic Acids during their Metabolism
Table 2: Marked elevation of phenylalanine is noted in the 
amino acid quantification report below which is suggestive of 
hyperphenylalaninemia.
Plasma Amino Acid Quantification
Test Result Unit Normal Range
Taurine
Aspartate
Threonine
Serine
Aspargine
Glutamate
Glutamine
Glycine
36
1
43
108
43
18
299
153
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
(19 139)
(0 - 16)
(36 - 136)
(42 - 174)
(26 - 70)
(24 - 68)
(337 - 709)
(74 - 290)
Alanine
Citrulline
Valine
Cystine
Methionine
Isoleucine
Leucine
Tyrosine
Phenylalanine
Ornithine
Lysine
Histidine
Arginine
Proline
109
20
92
28
5
28
63
35
1201
36
192
40
26
99
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
µmol/L
(144 - 348)
(6 - 34)
(79 - 267)
(43 - 67)
(9 - 29)
(32 - 92)
( 53 - 149)
(14 - 114)
(26 - 70)
(9 - 105)
(56 - 146)
(30 - 110)
(18 - 78)
(53 - 201)
Principle of Detection of Urine Organic Acids:
Organic acid analysis by Gas Chromatography-Mass 
Spectrometry (GC-MS) is critical for the diagnosis of 
organic acidurias. This technique 
is a combination of two powerful 
techniques: Gas chromatography 
and Mass spectrometry. GC can 
separate volatile and semi-volatile 
compounds with great resolution 
whereas MS can provide detailed 
structural information on most 
compounds such that they can be 
exactly identified. 
The process involves processing 
of sample followed by injection 
into the column via injector (Fig. 
2). The sample is then carried into 
the column by carrier gas ‘helium’ 
and the compounds in sample are separated on the 
basis on their boiling points and chemical structure 
as the column is heated. Effluent from GC passes 
through transfer line into the Ion trap/ Ion source 
where molecules then undergo electron ionisation 
(EI). These ions are then analysed according to their 
mass to charge ratio and are detected by electron 
multiplier which produces a signal proportional to 
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Fig. 2.  Analysis of Urine Organic Acid is in Progress
Courtesy of Section of Biochemical Genetics Laboratory, Aga Khan University 
Fig. 3.  Urine Organic Acid Chromatogram showing Markers of Hyperphe-
nylalaninemia Courtesy of Section of Biochemical Genetics Laboratory, 
Aga Khan University
ions detected resulting in a unique spectrum. Urine 
organic acid chromatogram achieved in a patient 
with ‘hyperphenylalaninemia’ is shown in Fig. 3.
Sample preparation is done in batches which take almost 
3.5 hours and the sample analysis time on instrument is 
35 minutes. All the peaks in chromatograms are matched 
with available organic acid libraries. After skillful 
interpretation the accurate diagnosis is made. 
Methylenetetrahydrofolate Reductase (MTHFR) 
is a rate-limiting enzyme in the methyl cycle. 
This enzyme is encoded by the MTHFR gene 
on chromosome 1 location p 36.3. It plays a 
vital role in folate metabolism, by catalyzing 
reduction of 5,10- methylenetetrahydrofolate to 
5-methylenetetrehydrofolate (Fig. 1), which is 
required for the multistep process that converts 
the amino acid homocysteine to another amino 
acid, methionine (Fig. 2). As human body requires 
methionine for protein synthesis, this is a critical 
enzyme. Mild to severe loss of enzyme activity 
results in elevated levels of homocysteine in 
blood and/or urine, leading to development delays 
and mental retardation. Elevated homocysteine 
levels may also cause irritation of blood vessels 
and clotting of blood in the veins. As a result of 
which, coronary artery disease leading to a heart 
attack or stroke may occur. In addition due to 
MTHFR deficiency body is unable to absorb folic 
acid which is essential for the development and 
health of the fetus.
Polymorphism in Methylenetetrahydrofolate 
Reductase (MTHFR) Gene
Zahida Amin Mir and Lamia Altaf
Molecular Pathology 
Fig. 1. Schematic diagram of the Reductive Carbon-nitrogen Bond 
Cleavage (represented by wavy line) Catalyzed by Methylenetetrahydro-
folate Reductase
Fig. 2. Overview of the Human Folic Acid Metabolic Pathway and the 
role of MTHFR S-adenosyl Methionine (SAM), S-adenosyl Homocysteine 
(SAH), Dihydrofolic Acid (DHF), Tetrahydrofolic Acid (THF), Dihydro-
Folate (DHF), Methionine Synthase (MTR), Thymidylate Synthase (TS)
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MTHFR Gene Polymorphism
The two major single nucleotide polymorphisms 
(SNP) associated with MTHFR are C677T and 
A1298C.
C677T SNP (Ala222Val)
The MTHFR nucleotide at position 677 in the 
gene has two possibilities, C (cytosine) or T 
(thymine). C at position 677 (leading to an alanine 
at amino acid 222) is the normal allele. The 677T 
allele (leading to a valine substitution at amino 
acid 222) encodes a thermolabile enzyme with 
reduced activity. Individual with two copies of 
677C (677CC) have the “normal” or “wildtype” 
genotype. 677TT individuals (homozygous) are 
said to have mild MTHFR deficiency. 677CT 
individuals (heterozygotes) are almost the same as 
normal individuals because the normal MTHFR 
compensate for the thermolabile MTHFR.
A1298C SNP (Glu429 Ala)
At nucleotide 1298 of the MTHFR, there are 
two possibilities: A or C. 1298A (leading to a 
Glu at amino acid 429) is the most common 
while 1298C (leading to an Ala substitution at 
amino acid 429) is less common. 1298AA is the 
“normal” homozygous, 1298AC the heterozygous 
and 1298CC the homozygous for the “variant”. 
The protein encoded by 1298C cannot be 
distinguished from 1298A in terms of activity, 
thermolability, flavin adenine dinucleotide 
release, or the protective effect of 5-methyl-tetra 
hydro folic acid. The C mutation does not appear 
to affect the MTHFR protein. It does not result 
in thermolabile MTHFR and does not appear to 
affect homocysteine levels.
MTHFR Genotyping
DNA is isolated from blood and subjected to in vitro 
amplification for the desired regions of the MTHFR 
gene codons 677 and 1298 using sequence specific 
primers. The amplified  products are analyzed by 
gel electrophoresis followed by ethidium bromide 
stainingThe amplified PCR products (MTHFR) are 
subjected to Hinf I for codon 677 and Mbo II for 
codon 1298 restriction enzyme digestion at 37°C 
overnight. The PCR products subjected to enzyme 
digestion are visualized on 3% agarose gel stained 
with ethidium bromide. 
For MTHFR 677, the PCR yielded a 198 bp product, 
which on digestion with Hinf I produced a 175 and 
23 bp fragments for TT condition (homozygous 
polymorphic) and a 198,175 and 23 bp fragments 
for CT condition (heterozygous polymorphic). An 
undigested product length of 198 bp was retained 
by the wild types (Fig. 3A). For MTHFR 1298 
genotyping PCR conditions were same as that 
of MTHFR 677 and the product yielded a 241bp 
fragment. AA genotype (wild type) on digestion 
with Mbo II, yield two fragments of sizes 204 and 
37, CC genotype (homozygous polymorphic) after 
digestion retained the 241 fragment size and AC 
genotype (heterozygous polymorphic) produced 
three fragments of size 241,204 and 37bp (Fig. 3B).
Fig. 3B. Gel Electrophoresis 
showing A1298C Single Nucleotide 
Polymorphism
Fig. 3A. Gel Electrophoresis 
showing C677T Single Nucleotide 
Polymorphism
and its metabolites; succinylacetone and 
succinylacetoacetate in the liver, resulting in severe 
liver disease. (Fig. 1) Tyrosine may also accumulate 
in the kidneys and central nervous system. 
Others types of tyrosinemia includes type II 
Diagnosis of Tyrosinemia Type I
Nasir Ali  
Chemical Pathology
Tyrosinemia type I is an autosomal recessive 
disorder characterized by lack of the enzyme 
fumarylacetoacetate hydrolase (FAH), which is 
needed to break down the amino acid tyrosine. 
Failure to properly break down tyrosine 
leads to abnormal accumulation of tyrosine 
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and III. Tyrosinemia type II, also known as 
oculocutaneous tyrosinemia, characteristically 
effects the cornea and skin, and is caused by 
deficiency of tyrosine aminotransferase, which acts 
at the first step in tyrosine catabolism. Tyrosinemia 
type III is a rare disorder caused by deficiency of 
4-hydroxyphenylpyruvate dioxygenase (4HPPD). 
In addition to the three inherited disorders, transient 
tyrosinemia of the newborn is the major cause of 
tyrosine elevations detected on newborn screening.
Patient with tyrosinemia may present with symptoms 
Fig. 1. Pathway for Degradation of Tyrosine showing the Defect in 
Tyrosinemia Type 1 and the point of Action of NTBC
Highlights of Metabolic Services at Clinical 
Laboratory of AKUH
Azeema Jamil, Rakshanda Mahar, Farhat Jahan, Nasir Ali 
Chemical Pathology
Specimen Collection and Submission
Three types of specimens can be submitted at AKUH 
Clinical Laboratory to perform specialized tests 
related to amino acid, urine organic and fatty acid 
oxidation disorders. For plasma amino acid detection 
in blood, only a few millilitres, 2-4 ml of venous 
blood in tube containing lithium heparin (green top) 
is required. Fasting specimen (at least two hours for 
infants and four hours for children) is preferred to 
avoid the increase of most amino acids after a meal 
intake. 
within the first few months of life and may include 
diarrhea, bloody stools, failure to thrive, vomiting, 
lethargy, irritability, and a “cabbage-like” odor to 
the skin or urine. If untreated, liver problems such as 
hepatomegaly jaundice, easy bleeding/bruising, and 
swelling of the legs/abdomen are common. Kidney 
problems can cause rickets and delays in walking. 
Without treatment, liver and kidney problems usually 
lead to death. Periodic episodes of pain/weakness 
(particularly in the legs), tachycardia, breathing 
problems, seizures, and coma may occur. 
The diagnosis of tyrosinemia is confirmed by 
measuring the elevated levels of tyrosine often with 
methionine and perhaps generalized aminoacids 
in the blood and organic acids along with 
‘succinylacetone’ in the urine. Enzyme testing and 
genetic testing of the FAH gene may also be used to 
confirm the diagnosis. 
Only 2-5 ml spot (untimed) urine is required for 
analysis of succinylacetone. Succinylacetone 
is photosensitive therefore protection of urine 
from light is advised. It can easily be done by 
wrapping the container with dark plastic bag. Urine 
succinylacetone is reported in mmol/mol creatinine 
and is normally not detected in urine.
Once diagnosed, children with tyrosinemia 
are treated with a medication called nitisinone 
(previously called NTBC). A diet low in tyrosine, 
phenylalanine, and methionine, and a special medical 
formula is often recommended. In the long term, 
individuals with liver damage or liver cancer may 
require a liver transplant. Treatment can prevent 
liver disease, kidney problems, and the neurological 
problems that can be associated with tyrosinemia. 
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Only 2-5 ml of urine collected in a clean sterile 
bottle is required for amino acid quantification in 
urine, qualitative detection of organic acids and 
quantification of succinylacetone. Urine can be 
collected anytime during the day. However, an 
early morning sample of urine is preferred.
The third specimen type in which quantification 
of amino acid is performed is Cerebrospinal fluid 
(CSF). The CSF is collected by the patient’s 
concerned doctor in a sterile container/ micro-
tube. Only 0.5 ml clear CSF is required for the 
analysis along with 2 ml whole blood collected 
in lithium heparinized tube. Plasma amino acid 
quantification is required to calculate the ratio 
between CSF and plasma amino acids. For 
analysis minimum acceptable volume of separated 
plasma, urine and CSF is 0.2 ml (200 µl). It 
is advisable to collect sample for laboratory 
tests related to IEM when symptoms are most 
pronounced in patient and before start of any 
treatment.
Specimen Transportation
For transportation of above specimens few 
important things must be followed. The most 
important one for plasma amino acid is that blood 
should be transported to laboratory on ice within 
four hours where it should be centrifuged and 
separated plasma should be stored at minus - 
20°C. If the sample is collected  outside AKUH 
then separated plasma should be transported to 
laboratory in dry ice. Freezing of whole blood 
collected in tube containing lithium heparin is 
prohibited.
Urine sample should also be frozen if the 
transportation time of more than four hours is 
required. For succinylacetone one more thing 
should be taken care of that is to avoid any light 
exposure.
CSF is very precious sample to analyze and it 
should be sent on ice immediately as collected. If 
CSF has to be transported from outside AKUH it 
should be transported in dry ice.
Specimen
There is a sample rejection policy at AKUH 
clinical laboratory where hemolyzed blood 
sample, stained CSF and unfrozen specimen 
received at laboratory are rejected. All specimens 
received at the processing bench in the  Section of 
Chemical Pathology are checked and received as 
per specimen collection policies. If any specimen 
is rejected  such as specimen collected in wrong 
tube, a telephone call is made to the provided 
contact number given at time of specimen 
deposition for request of fresh sample. 
Specimen Reporting
The turnaround time for amino acid quantification 
is 10 days and for urine organic acid is seven days 
after receiving the sample at Clinical Laboratory 
of AKUH. However, the stat testing of these 
tests within three days can be accomplished 
on physician request. Urine succinylacetone is 
performed on every Wednesday and the reporting 
is available on next Wednesday.
Coordination between Laboratory and treating 
Physician
All positive cases of IEM are discussed and 
reported to concerned physicians. 
Filling of History Form
Physicians need to fill the patient’s history 
form for all the tests being performed at the 
biochemical genetic lab for the diagnosis of IEM. 
This history form contains information regarding 
patient’s current health sign and symptoms along 
with patient’s detailed clinical history.
This history form is available at the Clinical 
Laboratory reception within AKUH as well 
as in all; Pediatric Ward, NICU, ER, etc in 
AKUH campus. It is also available at all 
AKUH phelebotomy centers within and outside 
Karachi. 
This is the sample copy of the form.
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Congenital Hypothyroidism
Dr  Noreen Sherazi
Chemical Pathology
Congenital hypothyroidism (CH) is one of the most 
common preventable causes of mental retardation 
that occurs due to thyroid hormones deficiency at 
birth. In most cases, the disorder is permanent. Less 
commonly, the altered neonatal thyroid function is 
transient, attributable to the transplacental passage of 
maternal medication, maternal blocking antibodies, 
or iodine deficiency or excess. 
CH is caused by an absent or defective thyroid gland 
classified into agenesis (22-42 per cent), ectopy (35-
42 per cent) and gland in place defects (24-36 per 
cent). There could be genetic defects of thyroxine 
or triiodothyronine synthesis within a structurally 
normal gland. In a small proportion of cases of 
CH, the defect is due to a deficiency of thyroid 
stimulating hormone (TSH), either isolated or as part 
of CH. (Fig. 1)
The signs and symptoms in CH may be so subtle 
that they can be easily missed. Excessive sleeping, 
reduced interest in nursing, poor muscle tone, 
low or hoarse cry, infrequent bowel movements, 
exaggerated jaundice, and low body temperature  
If fetal deficiency was severe because of complete 
absence (athyreosis) of the gland, physical features 
may include a larger anterior fontanel, persistence of 
a posterior fontanel, an umbilical hernia, and a large 
tongue (macroglossia) (Fig. 2).
In the developed world, nearly all cases of CH are 
detected by the newborn screening program. It is 
based on measurement of TSH or thyroxine (T4) 
on the second or third day of life. There could be 
high TSH or low T4 in individuals with CH. Two 
screening strategies for the detection of CH have 
evolved, a primary TSH/backup T4 method and a 
primary T4/backup TSH method. In addition, an 
increasing number of programs use a combined 
primary TSH plus T4 approach. This represents 
the ideal screening approach, especially once it is 
possible for FT4 to be measured accurately and 
cost-effectively in the eluates from filter-paper 
blood spots. Every infant should be tested before 
discharge from the nursery, optimally by 48 hours 
to four days of age. Specimens collected in the first 
24 to 48 hours of life may lead to false-positive TSH 
elevations when using any screening test approach. 
Newborn screening test results must beFig. 1. Metabolic Defect in Congenital Hypothyroidism
CONGENITAL 
HYPOTHYROIDISM (CH)
Normal Thyroid 
Gland
Congenital 
Hypothyroidism
Thyroid may be 
missing, misplaced, too 
small or not making 
enough harmone
Thyroid Hormone
Normal Cell and Body 
Function
Multiple Health and 
Growth Problems
Thyroid Hormone
Fig. 2. Features of congenital hypothyroidism 
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communicated rapidly back to the physician or 
hospital identified on the screening filter-paper 
card.
Most of the hereditary types of CH are inherited 
in an autosomal recessive manner with an 
incidence of 1:3000 to 1:4000 according to 
international data and mostly found to be of 
increased association with female gender and 
gestational age >40 weeks. Despite absence of a 
national program in Pakistan, individual hospitals 
like Aga Khan University Hospital (AKUH) 
and Shifa International have made an attempt to 
screen for CH. In the first two years of screening 
all newborns delivered at AKUH and four other 
maternity homes working under umbrella of 
AKUH were targeted, which included 5,000 
births. The first report that was published in JPMA 
1989 covers the initial 5000 children screened 
at AKUH and 997 babies screened at Shifa 
international over a three year period showing an 
incidence of 1:1000 for CH. Further in 2008, an 
audit of CH screening results was published from 
AKUH covering the data on 53,619 total births 
where TSH was done on 41,816 newborns out of 
which 10 cases were detected to be suffering from 
CH and an incidence of 1:16000 was reported.
The goal of newborn screening programs is to 
detect and start treatment within the first 1–2 
weeks of life. Treatment consists of a daily dose 
of thyroxine, available as a small tablet. The tablet 
is crushed and given to the infant with a small 
amount of water or milk. The most commonly 
recommended dose range is 10-15 μg/kg daily, 
typically 37.5 or 44 μg (Table 1). Within a few 
weeks, the T4 and TSH levels are rechecked 
to confirm that they are being normalized by 
treatment. As the child grows up, these levels 
are checked regularly to maintain the right dose. 
Persistence of severe, untreated hypothyroidism 
resulted in severe mental impairment, with 
an intelligence quotient (IQ) below 80 in the 
majority.
Most children born with CH and correctly treated 
with thyroxine grow and develop normally in 
all respects. Even most of those with athyreosis 
and undetectable T4 levels at birth develop with 
normal intelligence, although as a population, 
academic performance tends to be below that 
of siblings and mild learning problems occur in 
some.
Table 1.  Management of Congenital Hypothyrodism
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Congenital adrenal hyperplasia (CAH) refers 
to autosomal recessive diseases resulting from 
deficiency of enzymes involved in the production 
of cortisol by the adrenal glands. More than 90 per 
cent of cases of CAH are caused by 21-hydroxylase 
enzyme deficiency (21OHD). Severe deficiency 
produces classical form of CAH with ambiguous 
genetalia and salt wasting. However, mild deficiency 
of enzyme causes hidden late onset or non-classical 
CAH with non-specific presentation including 
hirsutism, acne, amenorrhea or infertility at later 
childhood, adolescence or after puberty.
Neonatal screening program for blood 17 OHP levels 
are intended to identify CAH cases of classical 
and non-classical forms in affected children before 
complication of salt wasting crises arises and for 
early diagnosis of late non-specific presentation, 
respectively. Screening of non-classical CAH 
through testing blood 17 OHP levels is corner stone 
for early diagnosis as disease presentation is non-
specific as well as late in onset. Levels of 17 OHP >4 
ng/ml is characteristic feature for disease suspicion 
in non-classical form in contrast to the diagnostic 
levels of  200 ng/ml  in classical form of CAH.
The non-classic form is one of the most common 
autosomal recessive diseases in some ethnic groups 
and one of the reasons of high prevalence of CAH 
is high rates of inter-marriages among same ethnic 
groups. Frequency of CAH is not known in Pakistan 
but expected to be  high due to increase rates of 
consanguineous marriages. The rationale of this is 
to determine the frequency of CAH among different 
age groups, gender and distribution in four provinces 
of Pakistan by evaluating the laboratory data of 
baseline blood 17-hydroxyprogesterone (17 OHP) 
levels. The findings of the report are presented in 
Table 1.
In a retrospective analysis, laboratory data of 
5853 samples tested for blood 17 OHP levels was 
examined. The samples were collected between 
period of 2007 to 2010, at the main laboratory of 
AKUH in Karachi and its 188 phlebotomy centers 
located in four provinces of Pakistan.  Subjects 
of all ages and gender were included with first 
time and baseline 17 OHP blood levels performed 
at clinical laboratory. Those were excluded with 
any follow up blood 17 OHP levels or stimulated 
with adrenocorticotropic hormone. On the basis 
of exclusion criteria data was edited for subject’s 
replication and a total of 2282 subjects were 
recruited with non-probability purposive sampling 
technique for final analysis. 17OHP results were 
grouped on the basis of locations of subjects, from 
where the test was ordered into Sindh, Baluchistan, 
Punjab and Khyber Pakhtunkhwan (KPK). Subjects 
were further categorized into four different age 
groups and three gender groups and frequency was 
observed for each age group and gender.
Our data showed an annual increasing frequency of 
blood 17 OHP levels screening (16.3 per cent, 16.9 
per cent, 20.4 per cent and 46.4 per cent through the 
years from 2007 to 2010 respectively).  Similarly 
an increasing trend was also seen annually, for 
frequency of subjects with suspected CAH (blood 17 
OHP levels ≥ 4ng/ml) as 5.1 per cent, 6.5 per cent, 
7.1 per cent and 15.7 per cent respectively through 
the years 2007 to 2010. In general, screening for 
CAH was observed to perform for different age 
groups and genders. However, first time screening 
was predominantly performed in female population 
and after 15 years. 
Overall, 34.4 per cent subjects were observed to 
have 17 OHP blood levels ≥ 4ng/ml with suspicion 
of CAH.  Majority of subjects with 17 OHP levels ≥ 
4ng/ml were from infant age group (≥1 month to ≤ 1 
year). With respect to gender, mostly females were 
found positive for suspicion of CAH in comparison 
with other genders (p = 0.0001). Variable percentages 
were observed for referrals of 17 OHP levels from 
different provinces but majority were referred from 
Sindh (73.4 per cent). The demographic details of the 
subjects are shown in Table 1.
Congenital Adrenal Hyperplasia, an Insight of 
Laboratory Data and Frequency Status
Dr Sahar Iqbal and Dr Aysha Habib Khan
Chemical Pathology
Reproduced from JCPSP
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As discussed earlier from positive cases (33.4 per cent), 
most of the suspected cases were infants (14.4 per 
cent), reflecting the importance of neonatal screening. 
However we observed that CAH screening was most 
commonly ordered in elder age group (after 15 years). 
This late screening may be explained by the late 
emergence of non-classical CAH signs and symptoms. 
Variable frequency of referrals from different provinces 
of Pakistan was observed as shown in Table 1. 
Higher frequency of cases with suspected CAH was 
observed from Sindh (23.7 per cent) as compared to 
other provinces. The most likely reason of this higher 
frequency from Sindh may be dependent on numbers of 
referrals from the Province (73.4  per cent). In Sindh we 
observed that from Karachi, 68 per cent of the samples 
were collected from a large number of (78) phlebotomy 
centers and main AKU campus. We also received 5.4 
per cent of samples from others phlebotomy centers 
located in different cities of Sindh other than Karachi, 
but we found Karachi city as the main hub for 17 OHP 
referrals from Sindh province, which may be due to 
large number of phlebotomy centers. However, beside 
AKU clinical laboratory, the blood testing of 17 OHP is 
also offered by other laboratories in Punjab and Sindh. 
From this laboratory data we could not conclude about 
the ethnicity of subjects with blood 17 OHP ≥ 4 ng/dl, 
but it could be presumed that CAH exists throughout 
the country with variable frequency. This finding was 
also supported by the results of a previous study from 
Pakistan where Khan et al also reported presence of 
CAH in different ethnic groups. 
The importance of establishing neonatal screening 
programme for CAH is enhanced by our present 
data. However, the benefits of screening for any 
disease in a state are dependent on the existing 
healthcare system. The treatment or management 
of inborn disorders has not been acknowledged 
appropriately in Pakistan. Additionally the existing 
healthcare system generally does not address 
complex issues commonly seen in genetic disorders 
including CAH patients.
In conclusion, the present laboratory data first time 
determine the frequency of suspected CAH (33.4 
per cent) in Pakistan. However, incidence of CAH 
remains unidentified due to absence of new born 
screening program, diagnostic testing, and lack of 
disease awareness in the society and failure of case 
identification by primary physician. The need of 
developing a team of expertise is crucial for early 
identification and management of CAH to reduce 
the morbidity and mortality. A well-structured and 
appropriate screening program should be instituted. 
The establishment of CAH registry is also critical at 
regional or national levels for the identified cases and 
respective prenatal treatment.
Table 1.  Demographic features and Distribution of subjects among different Provinces of Pakistan Tested for Blood 17 OHP levels at 
Aga Khan University Clinical Laboratory during  2007 - 2010 (n=2282)
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Cystic fibrosis (CF) is an autosomal recessive 
genetic disorder that affects lungs, pancreas, liver, 
and intestine. CF is caused by a mutation in the 
gene for the protein cystic fibrosis transmembrane 
conductance regulator (CFTR). This protein is 
required to regulate the components of sweat, 
digestive fluids, and mucus. CFTR regulates the 
movement of chloride and sodium ions across 
epithelial membranes, such as the alveolar epithelia 
located in the lungs. 
Discovery of CFTR Gene
This gene localized to 7q21-34 on long arm 
chromosome 7, was discovered in 1985 and its gene 
sequencing was done in 1989. The gene shown to 
encode a 1480 amino acid protein, CFTR. This protein 
has long linkage of amino acids, where they play the 
role of a brick/block. If any of these bricks are missing 
or abnormal, then the protein may not work properly. 
More than 1500 CF mutations have been reported, many 
of which are rare and some of which may not result in 
clinical signs or symptoms. The various mutations affect 
the function of CFTR in different ways.
Mode of inheritance and Risk of Passing on the 
CF Gene
CF has a simple Mendelian autosomal recessive 
inheritance pattern (Fig. 1). This shows that people 
with CF have two copies of the mutant CFTR 
gene, one inherited from each parent. Carriers have 
one normal and one mutant CFTR gene and their 
health is not affected because the normal CFTR 
gene ensures production of enough protein to allow 
normal cellular function. Carriers have a 50 per cent 
chance of passing their mutant CFTR gene onto their 
children. When both parents are carriers there is a 25 
per cent chance in every pregnancy that the child will 
have CF, a 25 per cent chance that the child will have 
two normal CFTR genes and a 50 per cent chance 
that the child will be a carrier.
At Aga Khan University Hospital Clinical 
Laboratory have the facility of Delta F508 mutation 
and sweat conductivity tests for cystic fibrosis.
Sweat Testing
It is recommended that sweat conductivity, which is 
related to the concentration of all ions, not just chloride, 
should only be used as a screening test. Several recent 
studies have demonstrated that measurement of sweat 
conductivity can reliably differentiate patients with CF 
from those without the condition.
Precautions: Because of a report of transient 
elevations in sweat electrolyte concentrations in 
the first 24 hours after birth, it is recommended that 
patients be at least 48 hours old before undergoing 
a sweat test. Before starting the procedure it should 
be made sure that the child is physiologically 
and nutritionally stable, well hydrated, is not 
suffering from any acute illness and is not on 
mineralocorticoids. The skin should be free of cuts, 
rashes and inflammation.
Technique: It occurs in three phases: sweat 
stimulation, sweat collection and sweat analysis. 
Localized sweating is produced by iontophoresis 
of the cholinergic drug into an area of skin (usually 
forearm). Macroduct sweat collector is placed 
over the stimulated area and firmly strapped 
to the forearm for at least thirty minutes. After 
attachment, sweat becomes visible in the spiral tube 
of Macroduct within one to four minutes, depending 
on the relative elasticity of the skin and the subjects 
sweating rate. The emergent sweat is turned blue by 
contact with a small amount of blue water soluble 
dye applied to the Macroduct collection surface. 
Sweat collected is then analyzed in the Wescor’s 
conductivity cell.
About Cystic Fibrosis 
Dr Zeeshan Ansar Ahmed and Dr Lena Jafri
Molecular Pathology and Chemical Pathology
Fig. 1. Simple Mendelian Autosomal Recessive Inheritance. Affected 
individuals will have two copies of the Mutant CFTR Gene, one Inherited 
from each parent.   
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Interpretation:  0-60 mmol/L - normal
    60-80 mmol/L - a possible indication of CF
   >80 mmol/L - definitive indication of CF
Failure to produce sweat: An insufficient sweat 
sample is not uncommon. It can be due to several 
factors such as dehydration, illness, age, race, 
skin condition, and issues in collection system.  
Differences in skin resistance because of ethnicity or 
individual patient variability may lead to insufficient 
sample volume. For example, in the United States a 
higher prevalence of ‘quantity not sufficient’ samples 
have been reported with black patients than with 
white patients.
Significance of Δ F508
In all CF mutations, the most common worldwide 
mutation is delta F508, which is around 70-82 
per cent. it is more common in western countries 
but also seen in other ethnic groups but the range 
of mutations are different e.g. in Ashkenazi 
Jews delta F508 accounts for 27 per cent and 
W1282X for 51per cent of the mutations. Delta 
F508 mutation is a three base-pair deletion in 
exon 10 of the CFTR gene results in the omission 
of phenylalanine (one of the bricks) at position 
508 in the 1480 amino acid chain. A mutant 
CFTR protein which cannot be folded into its 
proper shape is produced. The quality control 
mechanisms within the cell destroy this abnormal 
protein before it can reach the cell surface where 
its major normal function is to act as a channel 
through which chloride ions can pass in and out of 
the cell.
Detection of Mutation, Delta F508 in CF
DNA is extracted from blood and amplified by 
ARMS PCR. ARMS assay comprises two reaction, 
that is identification of specific mutation by two 
primers, one complementary to normal and other to 
the mutant DNA sequences. The amplified product 
is separated by agarose gel electrophoresis Fig. 2. 
Normal allele contain 160 base pairs (bp) band 
with internal control (429 bp), Homozygous 
case shows mutant alleles (157bp) but in 
Heterozygous case in both normal and mutant 
allele seen.(Lane one  & five are patient, two 
& six negative control , three & seven positive 
control for both normal & mutant allele and 
lane four is band size marker).
Fig. 2. Detection of Mutation, Delta F508
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Aga Khan University Hospital (AKUH) always 
strives to introduce new Service Excellence 
projects to improve quality care. Introducing the 
laboratory diagnostic services for Inborn Error of 
Metabolism (IEM) in Pakistan is one of the major 
achievement of Clinical Laboratory in the current 
year (2013). State-of-the-art techniques such as 
high performance liquid chromatography (HPLC) 
and gas chromatography and mass spectrometry 
(GC-MS) are introduced for detection of IEM 
disorders.
To make it happen, in the year 2011, a team of 
Chemical Pathologists comprising of Dr Farooq 
Inauguration of Biochemical Genetics 
Laboratory: A Step to Strengthen Diagnostic 
Facilities 
Dr Farhan Javed Dar
Chemical Pathology
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Ghani and Dr Imran Siddiqui collaborated with 
Institute of Malaysia Research (IMR). This research 
institute is a specialized center for IEM testing, 
headed by Dr Zabedah Md Yunus, a Chemical 
Pathologist of Malaysia.  
In the first phase, two senior technologists and one 
pathologist from the section of Chemical Pathology 
visited IMR for four weeks training in October 2011 
on amino acids and organic acids chromatograms. In 
the next phase, Dr Aysha Habib Khan, went to IMR, 
Malaysia for training in September 2012 to improve 
and strengthen this service. 
On March 20th 2013 an official inauguration 
ceremony of section of Biochemical Genetics 
Laboratory was held. 
Mr Nadeem Mustafa Khan Regional CEO, Health 
Services, Asia (AKUH, Pakistan and FMIC, 
Afghanistan) and Dr Mohammad Khurshid, 
Professor and Founding Chair Department of 
Oncology inaugurated Section of Biochemical 
Genetics laboratory followed by a cake cutting 
ceremony. The inauguration ceremony was 
attended by Dr Naila Kyani and renowned 
pediatricians Drs Iqtidar Khan, Shahnaz Ibrahim, 
Bushra Afroze as well as other key officials of 
AKUH including Dr Nadeem Ahmed, Dr Zafar 
Sajjad, Mr Sohail Baloch at the Section of 
Chemical Pathology, Department of Pathology 
and Microbiology.  
The inauguration ceremony was followed by 
Continuing Medical Education Seminar at the 
Auditorium of AKU. Dr Farooq Ghani emphasized 
during the CME seminar  that the introduction of 
highly sophisticated chromatographic techniques 
has now made it possible to test a newborn for 
several genetic metabolic disorders simultaneously 
and informed the audiences how prompt detection 
substantially improves the prognosis for many 
of these conditions. Dr Bushra Afroze, metabolic 
physician at the AKUH was of the view that an 
Group photo during training at IMR Malaysia; Sep’ 2012
Courtesy of Dr Aysha Habib Khan
Ribbon cutting ceremony by Mr Nadeem Mustafa Khan, Dr Mohammad 
Khurshid and Dr Naila Kayani
Dr Bushra Afroze, Consultant  Clinical Geneticist, Assistant Professor, 
Department of Paediatics and Child HealthCake cutting ceremony
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Dr Anita Zaidi, Professor of Paediatics and Child Health Dr Naila Kayani, Chair Department of Pathology and Microbiology 
and Director Clinical Laboratory
affected baby could be treated and had every 
chance of growing normally. Dr Aysha Habib, 
the Head of the Section of Chemical Pathology 
at the AKUH, highlighted the issues and 
challenges and stressed on need for groups to 
work collaboratively, complementing each other’s 
capabilities and sharing training resources. The 
CME was inspired by the words of encouragement 
by the chief guest Professor of Pediatiorcs and 
Child Health, Dr Anita Zaidi. 
The ceremony and seminar ended with closing 
remarks of Professor Dr Naila Kayani, chairperson 
of the Department of Pathology and Microbiology 
and Director AKUH Clinical Laboratories. She 
lauded  AKUH Clinical Laboratories for successfully 
initiating testing for diagnosis of IEM on state-
of-the-art equipment, adding that this was another 
milestone after the launch of Pakistan’s first fully 
automated biochemistry laboratory at AKUH, 
Karachi in 2012.
‘Nutricia Advanced Medical Nutrition’ conducted 
full day workshops on Inborn Errors of Metabolism 
(IEM) in Karachi and Islamabad on 30th November 
and 2nd December 2013. Young pediatricians were 
welcomed by Global Product Manager of Nutricia 
Turkey, Mr A. Cem Atey. Then Ms Negar Esmail-
zadeh, Medical Affairs Manager of Nutricia, Turkey 
provided a global perspective of IEM followed by an 
interactive overview by Dr. Bushra Afroze, Con-
sultant Clinical Geneticist and Assistant Professor 
Department of Pediatrics and Child Health, AKUH. 
Dr. Lena Jafri, Instructor Department of Pathology 
and Microbiology, AKUH educated the participants 
on collection of critical samples in suspected IEM 
disorders.  This was further elaborated by Dr Bushra 
Afroze who conducted a session on ‘How to Deal 
with Metabolic Emergencies’. The second half of the 
conference commenced with Dr. Lena Jafri’s session 
on ‘What Pediatricians Need to Know about Urine 
Organic Acid and Plasma Amino Acid Analysis’. 
The latter half of the session was dedicated to group 
sessions on real life IEM cases.  The objective of the 
conference, to create awareness and build capacity in 
young doctors of the two metropolitan cities con-
cerning the diagnosis and management of IEM was 
effectively achieved. 
Workshop on “Inborn Errors of Metabolism” 
Problem Based Learning
Group picture of Workshop Facilitators and Nutricia representatives
hospitals.aku.edu/Karachi/clinical-laboratories
